Primer on Diabetes Management

Symposium on Diabetes and Cancer 2017: Novel Links and Treatments

S. Inzucchi

ACC 2022: An Embarrassment of Riches - Updated Guideline Recommendat…

ACC 2022 Conference Coverage

P. Heidenreich

ACC 2023: SGLT2i Use - Dos and Don'ts

ACC 2023 Conference Coverage

A. Armbruster

Obesity and Diabetes in Children

Ilene Fennoy

Diabetes Treatment Guidelines Finally Have Entered the 21st Century …

ASPC 2019 Congress on CVD Prevention

R. DeFronzo

Advancing Type 2 Diabetes Care with Omnipod® 5

Omnipod®

V. Shah, D. Kruger, T. Ly

Is There a Future for HbA1c? (Moving Towards CGM: GMI and TIR)

Practical Ways to Achieve Targets in Diabetes Care

I. Hirsch

Optimizing Omnipod® 5 for Better Patient Outcomes (featuring Jennife…

Omnipod®

J. Okemah

GLP-1/GIP Update: Stay Tuned... The Best is Yet to Come!!

Robert Busch

SURPASS 2: Tirzepatide Versus Once-Weekly Semaglutide

Juan Frias

Evidence that Obesity and Diabetes are Driven by a Diet-Induced Biol…

University of Colorado Department of Medicine

R. Johnson

Renal, Metabolic and Cardiovascular Considerations of SGLT2 Inhibiti…

Cardiology Fiesta 2017

R. DeFronzo

Mind over diabetes: a psychologist’s take on the freedom of Omnipod®…

Omnipod®

M. Heyman

Labs to Check on Semaglutide or Tirzepatide

Susan Brian

SGLT2 Inhibitors: For Heart Failure, Diabetes, and Renal Disease

Rita Jermyn

SGLT2 Inhibitors, GLP1 Receptor Agonists, and Renal Outcomes

Cardiometabolic Health Congress (CMHC)

L. Sloan

Could GLP-1's be a 'Game Changer' For Weight Loss? Can it be a Safer…

Ken Fujioka

Type 2 Diabetes and Omnipod® 5--Unveiling SECURE T2D

Omnipod®

F. Pasquel

Tirzepatide Updates

Diana Isaacs

Weightloss in Menopause

Susan Brian